Children's National Medical Center Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 20:26

Focused ultrasound research expands possibilities for treating pediatric brain tumors - Children's National

Focused ultrasound research at Children's National is gaining momentum, with four upcoming or recently completed first-in-human clinical trials, two focused ultrasound platforms and three $1 million grants advancing treatment strategies for children with difficult-to-treat brain tumors.

Researchers are studying both high-intensity and low-intensity focused ultrasound, two approaches that use precisely targeted sound waves in different ways while minimizing harm to healthy brain tissue. Children's National is the first freestanding pediatric hospital in the world with this level of focused ultrasound capability dedicated to pediatric brain tumor research.

"Focused ultrasound gives us a highly precise, adaptable platform to explore new ways of treating some of the most challenging pediatric brain tumors," said Roger J. Packer, MD, director of the Brain Tumor Institute at Children's National. "By combining this technology with drug delivery, immunotherapy and cellular therapy, we are working to expand treatment options while minimizing harm to the developing brain."

The big picture

High-intensity focused ultrasound (HIFU) concentrates ultrasound energy to generate heat and precisely destroy targeted tissue without an incision. Researchers are exploring its potential applications for pediatric brain tumors and other neurological conditions, including cerebral palsy.

Low-intensity focused ultrasound (LIFU) uses lower levels of energy and can be paired with other treatments. One promising application involves temporarily disrupting the blood-brain barrier, which protects the brain but can also prevent cancer therapies from reaching tumors in sufficient concentrations.

At Children's National, four first-in-human clinical trials are exploring LIFU for children with brain tumors.

Executing these complex studies requires a multidisciplinary team spanning neurology, neuro-oncology, oncology, neurosurgery, anesthesiology, neuroradiology, critical care medicine and nursing.

Moving the field forward

Two studies have already been completed. One combined focused ultrasound with 5-aminolevulinic acid, or 5-ALA, for diffuse intrinsic pontine glioma (DIPG). Seventeen patients received more than 50 treatments across Children's National and collaborating institutions, providing important experience with repeated focused ultrasound treatments targeting the brainstem.

Another trial used LIFU and microbubbles to temporarily disrupt the blood-brain barrier before administering doxorubicin. Six patients with DIPG received 13 treatments at Children's National and SickKids, providing early clinical evidence for using the approach to facilitate drug delivery.

Two new first-in-human trials are taking the research further. NgFUS NIVO will combine blood-brain barrier disruption with nivolumab for recurrent DIPG and other high-risk central nervous system tumors. LIFT will combine the approach with tumor-associated antigen-specific T cells for diffuse midline glioma (DMG), expanding the research beyond DIPG to non-brainstem DMG.

Why we're excited

Three $1 million grants awarded to Children's National over the past year are accelerating research at the intersection of focused ultrasound and cellular therapy for pediatric brain tumors.

A grant from the Focused Ultrasound Foundation supports the LIFT trial, which will investigate whether temporarily opening the blood-brain barrier can improve the delivery of tumor-associated antigen-specific T cells to DMG and enhance the immune response by modulating the tumor immune microenvironment. This research is led by Luca Szalontay, MD, neuro-oncologist at Children's National, and Dr. Packer.

A second grant from Lotus Neuro supports the Brain Tumor Institute's broader cellular therapy and LIFU and HIFU research, led by Dalia Haydar, PharmD, PhD, principal investigator for the Cell Enhancement and Technologies for Immunotherapy (CETI) Program at Children's National.

A third grant, from the Cure Starts Now Foundation supports a novel approach that uses focused ultrasound to activate CAR T cells. The research is led by Dr. Haydar in collaboration with Cheng-Chia "Fred" Wu, MD, PhD, assistant professor at Virginia Tech.

These grants build on a landmark gift from an anonymous family helping to advance focused ultrasound as part of its broader support for brain tumor research and care.

"We are deeply grateful for this transformative support," said Dr. Packer. "By bringing together focused ultrasound and cellular therapy, we can pursue innovative ways to deliver treatments more effectively to difficult-to-treat tumors and accelerate promising options for children who urgently need them."

What's next

Focused ultrasound research at Children's National extends from the laboratory to clinical trials. Researchers are studying additional treatment combinations, including whether focused ultrasound can help CAR T cells cross the blood-brain barrier.

Together, the work is creating a pipeline to move focused ultrasound from early clinical testing toward new strategies for drug delivery, immunotherapy, cellular therapy and precise treatment of pediatric brain tumors.

We gratefully acknowledge the following organizations for their support of the Cure Starts Now grant: The Cure Starts Now Foundation; The Cure Starts Now Australia; The Cure Starts Now Canada; Melina Michelle Edenfield Foundation; Brooke Healey Foundation; Reflections Of Grace Foundation; The Ayla Foundation; Yuvaan Tiwari Foundation; Musella Foundation for Brain Tumor Research & Information, Inc.; and Run DIPG.

Read more about how researchers are using focused ultrasound to advance research at Children's National here.

Children's National Medical Center Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 21, 2026 at 02:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]